Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MedImmune Ventures leads Hydra's Series D round

Executive Summary

Hydra Biosciences (developing ion channel therapeutics) raised $22mm through its Series D round, which was led by MedImmune Ventures and included returning investors Advanced Technology Ventures, Abingworth, Polaris Venture Partners, BioVentures Investors, Biogen Idec New Ventures, and Lilly Ventures. An executive from AstraZeneca, as designee for MedImmune and MedImmune Ventures, will take a seat on Hydra's board. The company will use the proceeds to advance its Transient Receptor Potential ion channel drug programs into clinical trials for pain, inflammation, and pulmonary diseases.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies